फाइज़र शेयर की कीमत

ड्रग मेकर का उद्देश्य बेरोबेनेटाइड को पहला मासिक GLP-1 वेट-लॉस इन्जेक्शन बनाना है, जो इसे वेगोवी और एलि लिली के ज़ेपबाउंड जैसी ब्लॉकबस्टर दवाओं से अलग करता है

• बिजनेस लाइन
• 1 दिन 18 घंटे पहले

सहयोग में 12 ऑन्कोलॉजी प्रोग्राम का पोर्टफोलियो बनाया गया है, जिसमें आठ इनोवेंट-ओरिजिनेटेड अर्ली-स्टेज एसेट और चार फाइज़र-प्रस्तावित डिस्कवरी प्रोग्राम शामिल हैं

• बिजनेस लाइन
• 1 सप्ताह 3 दिन पहले

Pharmaceuticals company Pfizer announced Q4FY26 & FY26 results Financial Highlights: Revenue from Operations: For Q4FY26, the revenue stood at Rs 629.23 crore, a growth of 6.30% YoY compared to Rs 591.91 crore in Q4FY25. On a QoQ basis, it decreased by 2.45% from Rs 645.03 crore in Q3FY26. For FY26, revenue from operations was Rs 2,519.65 crore, compared to Rs 2,281.35 crore in FY25, representing a YoY increase of 10.45%. Total Income: The total income for Q4FY26 was Rs 669.95 crore, up 5.26% YoY from Rs 636.49 crore in Q4FY25, but down 1.95% QoQ from Rs 683.24 crore in Q3FY26. Annual total income for FY26 reached Rs 2,707.60 crore against Rs 2,453.60 crore in FY25. Profit Before Tax and Exceptional Items: For Q4FY26, profit before tax and exceptional items was Rs 259.78 crore, a marginal increase of 2.68% YoY from Rs 252.99 crore in Q4FY25 and an increase of 3.85% QoQ from Rs 250.15 crore in Q3FY26. For FY26, this parameter stood at Rs 1,024.83 crore compared to Rs 843.28 crore in FY25. Net Profit: Net profit for Q4FY26 was Rs 199.82 crore, a decrease of 39.62% YoY from Rs 330.94 crore in Q4FY25 (which included higher exceptional gains). However, it grew by 40.88% QoQ from Rs 141.84 crore in Q3FY26. For FY26, net profit was Rs 722.43 crore compared to Rs 767.60 crore in FY25, a YoY decline of 5.88%. Business Highlights: Segment Performance: The Company operates in a single segment, which is 'Pharmaceuticals'. Therefore, segment-wise disclosure is not applicable. Dividend: The Board of Directors recommended a final dividend of Rs 75 per equity share of Rs 10 each (750%) for the financial year ended March 31, 2026, amounting to Rs 343.11 crore. Exceptional Items: The company recorded a total exceptional charge of Rs 49.16 crore for FY26, which includes: Rs 41.73 crore towards personnel separation costs for the field force and marketing teams following an exclusive Supply and Marketing Agreement with Cipla Limited for four brands (Corex Dx, Corex LS, Dolonex, and Neksium). Rs 7.43 crore towards an increase in the provision for employee benefits resulting from an assessment of the 'New Labour Codes'. Exceptional Items: The previous year FY25 included a net gain of Rs 172.81 crore from the assignment of a lease of MIDC Land and the sale of a building. Auditor Appointment: M/s. Kishore Bhatia & Associates were appointed as the Cost Auditors for the financial year ending March 31, 2027. Result PDF

• ट्रेंडलाइन
• 3 सप्ताह 5 दिन पहले